Sponge60 said...
Yes, I would probably consider HDR Boost overkill for my situation as well being favorable intermediate but location is everything too. Mine's at the bed near the bladder... It appears to me that HDR BT being an internally placed source with very good dose control is very attractive to limiting involvement of nearby organs and can reach several mm into outer areas.
location matters in real estate, not prostate cancer. It's either localized (Stage T2) or it isn't. How did you get a diagnosis of being in the prostate bed, which would be Stage T3a? You seem to understand that HDRBT can even treat areas outside of the prostate, yet you worry about
where it is -- the two statements are contradictory. The 95% success of HDRBT monotherapy in intermediate risk PC has been proved based on
clinical diagnosis (and without any diagnostic "assistance" from Decipher). However, if you have a diagnosis of stage T3a (in the prostate bed), you are high risk - so can you clarify your statement? If you have been diagnosed as high risk, HDRBT has been used in a few clinical trials with excellent outcomes, but the boost would be the standard of care:
/pcnrv.blogspot.com/2016/08/hdr-brachy-boost-and-monotherapy-for.htmlGammaKnife is not used for prostates - you mean CyberKnife. Insurance clerks rubberstamp denials all the time - just appeal.
Sponge60 said...
Proton therapy, also being attractive to other tissues w/its deposit of high energy in a specific area with no exit beam dose. It can also reach out and paint with a pencil beam outer areas of interest. Looks like the additive neutron dose is non-significant as well for proton treatment.
You swallowed the Kool-Aid. The Bragg Peak is a theoretical framework. There are secondary particles, diffraction from the nozzle, and spread due to charge repulsion. The real life toxicity is no different from IMRT, BT or SBRT. Sexual toxicity seems to be worse.
/pcnrv.blogspot.com/2016/08/proton-therapy-at-university-of-florida.html